GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk

Core Viewpoint - GSK's RSV vaccine, AREXVY, has received approval in the US for an expanded age indication, now including adults aged 18–49 years who are at increased risk [1] Group 1 - The approval of AREXVY marks a significant milestone for GSK in addressing respiratory syncytial virus (RSV) in a broader adult population [1] - The vaccine is specifically targeted at adults aged 18–49 years who are considered to be at increased risk, expanding its potential market [1]